Nivolumab (NIVO) safety in patients with advanced melanoma (MEL) who have progressed on or after ipilimumab (IPI): A single-arm, open-label, multicenter, phase II study (CheckMate 172). - Ascierto, PA; Demidov, LV; Garbe, C; Lorigan, P; Gogas, H; Hoeller, C; Haanen, JBAG; Espinosa, E; Guren, TK; Munoz-Couselo, E; Rorive, A; Rutkowski, P; et al. (Journal Of Clinical Oncology, 2016)